

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2016218635 B2**

(54) Title  
**Molecular design of recombinant protein drug**

(51) International Patent Classification(s)  
**C07K 14/435** (2006.01)      **A61P 3/04** (2006.01)  
**A61K 38/17** (2006.01)      **A61P 5/50** (2006.01)  
**A61P 1/16** (2006.01)      **A61P 35/00** (2006.01)

(21) Application No: **2016218635**      (22) Date of Filing: **2016.02.14**

(87) WIPO No: **WO16/127948**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>201510736184.2</b>	<b>2015.11.02</b>	<b>CN</b>
<b>201510079486.7</b>	<b>2015.02.13</b>	<b>CN</b>

(43) Publication Date: **2016.08.18**

(44) Accepted Journal Date: **2020.07.23**

(71) Applicant(s)  
**Tsinghua University;Beijing Protgen Ltd.**

(72) Inventor(s)  
**Luo, Yongzhang;Liu, Peng;Lu, Xinan**

(74) Agent / Attorney  
**Phillips Ormonde Fitzpatrick, PO Box 323, Collins Street West, VIC, 8007, AU**

(56) Related Art  
**EP 2754718 A1**  
**CN 101890155 A**

## (12) 按照专利合作条约所公布的国际申请

(19) 世界知识产权组织  
国际局



(43) 国际公布日  
2016 年 8 月 18 日 (18.08.2016) WIPO | PCT

(10) 国际公布号  
WO 2016/127948 A1

(51) 国际专利分类号:

C07K 14/435 (2006.01) A61P 3/04 (2006.01)  
A61K 38/17 (2006.01) A61P 1/16 (2006.01)  
A61K 47/48 (2006.01) A61P 5/50 (2006.01)  
A61P 35/00 (2006.01)

(21) 国际申请号:

PCT/CN2016/073773

(22) 国际申请日:

2016 年 2 月 14 日 (14.02.2016)

(25) 申请语言:

中文

(26) 公布语言:

中文

(30) 优先权:

201510079486.7 2015 年 2 月 13 日 (13.02.2015) CN  
201510736184.2 2015 年 11 月 2 日 (02.11.2015) CN

(71) 申请人: 清华大学 (TSINGHUA UNIVERSITY)

[CN/CN]; 中国北京市海淀区清华园 1 号, Beijing 100084 (CN)。北京普罗吉生物科学发展有限公司 (BEIJING PROTGEN LTD.) [CN/CN]; 中国北京市海淀区开拓路 5 号 B412, Beijing 100085 (CN)。

(72) 发明人: 罗永章 (LUO, Yongzhang); 中国北京市海

淀区清华园 1 号, Beijing 100084 (CN)。刘鹏 (LIU, Peng); 中国北京市海淀区开拓路 5 号 B412, Beijing 100085 (CN)。鲁薪安 (LU, Xinan); 中国北京市海

(74) 代理人: 北京华睿卓成知识产权代理事务所 (普通合伙) (CHENG & PENG INTELLECTUAL

PROPERTY LAW OFFICE); 中国北京市东城区东直门外大街 42 号宇飞大厦 821, Beijing 100027 (CN)。

(81) 指定国 (除另有指明, 要求每一种可提供的国家保护): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW。

(84) 指定国 (除另有指明, 要求每一种可提供的地区保护): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), 欧亚 (AM, AZ, BY, KG, KZ, RU, TJ, TM), 欧洲 (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)。

本国际公布:

- 包括国际检索报告(条约第 21 条(3))。
- 包括说明书序列表部分(细则 5.2(a))。



WO 2016/127948 A1

(54) Title: MOLECULAR DESIGN OF RECOMBINANT PROTEIN DRUG

(54) 发明名称: 一种重组蛋白质药物的分子设计

(57) Abstract: Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.

(57) 摘要: 提供了一种血管内皮抑制素的突变体, 所述突变体具有提高的 ATPase 活性和提高的抑制新生血管生成和抑制肿瘤的活性。还提供了所述突变体在治疗肿瘤等新生血管生成相关疾病中的用途。

## MOLECULAR DESIGN OF RECOMBINANT PROTEIN DRUG

### **Field of the Invention**

The present invention relates to novel recombinant protein drugs. Specifically, this invention provides variants of endostatin, wherein said variants have higher ATPase activity and higher activity of inhibiting angiogenesis and tumor growth compared to native endostatin. The present invention also provides the use of said variants in treating tumor and other angiogenesis-related diseases.

### **Background of the Invention**

In 1997, professor Judah Folkman of Harvard University discovered an endogenous angiogenesis inhibitor: endostatin (abbreviated as ES hereinafter). ES is an enzymatic digestion product from the carboxyl terminal of collagen XVIII, with a molecular weight of about 20 kDa, and comprises 183 amino acid residues. Recombinant endostatin can inhibit or even cure various murine tumors, without showing any drug resistance (Folkman J. et al. *Cell* 1997; 88:277-285; Folkman J. et al. *Nature* 1997; 390:404-407). The mechanism of ES in inhibiting tumor is to inhibit its angiogenesis, and to block nutrients and oxygen supply to the tumor.

Adenosine triphosphate (ATP) is the most basic energy source for life, and it is extremely important in maintaining life activities. Under normal physiological conditions, the molar concentration of ATP in cells and in blood is 1-10 mM and 100  $\mu$ M respectively. ATPase, also named as adenosine triphosphatase, is a class of enzymes which can catalyze the hydrolysis of ATP to release energy, and at the same time, produce adenosine diphosphate (ADP) and a phosphate ion (Pi). In addition, the high energy bond contained in guanosine triphosphate (GTP) can also provide energy for protein biosynthesis.

Many important proteins, such as Hsp90, myosin, and the like, depend on ATP for energy supply. These proteins themselves usually have ATPase activity. Although various ATPases differ in sequence and tertiary structure, they usually have an ATP-binding motif, i.e. the P-loop structure (Andrea T. Deyrup, et al., 1998, *JBC*, 273(16):9450-9456). A typical sequence for the P-loop structure is GXXGXXK (Driscoll, W. J., et al., 1995, *Proc. Natl. Acad. Sci. U.S.A.*, 92:12328-12332), wherein X denotes any amino acid residue, and the other amino acid residues (two Gs and a K) are relatively more conserved. Usually, the ATP-binding motif in these ATPases can also bind GTP, so many ATPases also have GTPase activity at the same time.

When bearing a tumor, cancer cells and neovascular endothelial cells have extremely exuberant metabolic activities, and the metabolism thereof is greatly different from that in normal mature cells. On the one hand, cancer cells and exuberantly proliferating cells need to consume large amount of ATP; on the other hand, the efficiency of the cancer cells and the exuberantly proliferating cells to produce ATP from glucose is rather low, and such a low efficiency method of ATP production by aerobic glycolysis is termed the “Warburg effect”. Although the efficiency of producing ATP in this method is very low, a lot of building blocks which can be used for cell structure assembly are produced during the process, which,

however, is more helpful to cell proliferation (Matthew G., et al., 2009, *Science*, 324:1029-1033).

Prior arts show that native endostatin has very high ATPase activity, and the amino acids Gly-Ser-Glu-Gly-Pro-Leu-Lys at positions 89-95 in its sequence (SEQ ID NO:1) have the classic ATP-binding motif in the form of GXXGXXK. Prior arts show that the ATPase activity of ES is negatively related to the activity of ES to inhibit endothelial cell migration, and this phenomenon can be explained by the Warburg Effect. This pattern has been proved and revealed in a series of ES mutants with decreased ATPase activity (PCT/CN2012/081210).

Throughout the description and claims of the specification, the word “comprise” and variations of the word, such as “comprising” and “comprises”, is not intended to exclude other additives, components, integers or steps.

A reference herein to a patent document or other matter which is given as prior art is not to be taken as admission that the document or matter was known or that the information it contains was part of the common general knowledge as at the priority date of any of the claims.

### **Summary of the Invention**

The present invention relates to the ATPase activity of ES, and ES drug designing based on such activity and ES mutants with higher anti-tumor activity are disclosed.

It is found by the present invention that, apart from the classic ATP-binding motif in the form of GXXGXXK, the native ES molecule also has another site associated with ATPase activity, i.e., an auxiliary binding motif, Val-Leu-Cys-Ile-Glu, at positions 171-175 in the native ES sequence (SEQ ID NO: 1), wherein said motif is in compliance with another classic form of ATP-binding motif: hhhhE (where h represents a hydrophobic amino acid residue).

It is also found by the present invention that only when the two ATP-binding motifs are coordinated, can the ATPase activity of ES be ensured. Within the two motifs, the site with GXXGXXK binding motif conducts main binding and catalysis functions, and the binding motif in the form of hhhhE has an important effect on the ATPase activity by influencing the binding status of ES and substrate ATP. Thus, the ATPase activity of ES can be altered by deletion, insertion or substitution of the amino acid residues in the two ATP-binding motifs.

In the present invention, the ATP-binding motif in the ES molecule having the form of GXXGXXK is termed Walker A Motif (i.e., the A Motif). The A motif plays a major catalytic role. The ATPase activity of ES can be increased or decreased by deletion, insertion or substitution of the amino acid residues in the A Motif.

In the present invention, the ATP-binding motif in the ES molecule having the form of hhhhE is termed Walker B Motif (the B Motif). The B Motif mainly helps ES to bind ATP and does not directly catalyze the hydrolysis of ATP. Therefore, deletion, insertion or substitution of the amino acid residues in the B motif only usually reduces the ATPase activity of ES. In theory, however, for a particular A motif, appropriate changes in the B Motif can also cause increased ATPase activity. Therefore, if ES mutants with improved ATPase activity are desired, the A motif and the B motif should be adjusted adaptively in drug designing.

It is found surprisingly by the present invention that for the ES mutants with significantly improved ATPase activity, their activity to inhibit endothelial cell migration and to inhibit tumor is significantly higher than that of native ES and ES mutants with decreased ATPase activity.

ES is an anti-angiogenesis protein, the most basic function of which is inhibiting angiogenesis by suppressing the activity of endothelial cells, and thus it can treat angiogenesis-related diseases, such as tumor, retinal macular degeneration, obesity, diabetes, and the like. We found that ES mutants with higher ATPase activity show improved activity in

inhibiting angiogenesis-related disease (such as tumor, obesity, fatty liver, insulin resistance, and the like) than native ES or ES mutants with decreased ATPase activity.

In addition, based on the discovery of the association between the anti-angiogenesis activity of ES and its ATPase activity, ES mutants can be designed by molecular cloning approaches to further alter (e.g., increase) the ATPase activity, and therefore to obtain ES drugs which better inhibit angiogenesis-related diseases such as tumor.

The present invention also provides a method to improve the anti-tumor activity of ES or variants thereof, which includes increasing the ATPase activity of ES or variants thereof. Specifically, a mutation can be introduced into the two ATP-binding motifs of ES or variants thereof by genetic engineering approaches, so as to obtain mutants of ES or variants thereof with increased ATPase activity, wherein said mutants have improved biological activity, such as increased activity of inhibiting endothelial cell migration and increased activity of inhibiting tumor.

The present invention also provides an ES mutant which has increased anti-angiogenesis activity, wherein said mutant contains a mutation in its ATP-binding motif, and has higher ATPase activity compared to wild-type ES or some variants thereof.

Preferably, when compared to wild-type ES, the ATPase activity of said ES mutant is increased by at least 100%, meaning the ATPase activity of said ES mutant is 200% of that of the wild-type ES, 300% of that of the wild-type ES, or higher. Compared to the engineering scheme of decreasing the ATPase activity, the engineering scheme of increasing the ATPase activity has greater space for optimization.

In some embodiments, when compared to the corresponding wild-type ES or variants thereof, mutant with increased ATPase activity includes a mutation in the A motif of its ATP-binding motifs. For example, said mutant contains a mutation in the sequence corresponding to the Gly-Ser-Glu-Gly-Pro-Leu-Lys motif consisting of amino acid residues at positions 89-95 of SEQ ID NO: 1, and wherein said mutation is selected from deletion, insertion or substitution of one or several amino acids, or the combination thereof, and wherein said mutation leads to the increase of the ATPase activity of said mutant.

In some embodiments, the sequence of said mutant corresponding to the A motif, i.e. the Gly-Ser-Glu-Gly-Pro-Leu-Lys motif consisting of amino acid residues at positions 89-95 of SEQ ID NO: 1, is mutated, wherein the mutation leads to the increase of ATPase activity of said mutant.

In some embodiments, said mutant contains a mutation in the B motif when compared to wild-type ES or variants thereof.

In some embodiments, the sequence of said mutant corresponding to the B motif, i.e. the Val-Leu-Cys-Ile-Glu auxiliary binding motif consisting of amino acid residues at positions 171-175 of SEQ ID NO: 1, is partially or entirely mutated.

It is also found by the present invention that, there is a C motif in ES (Walker C motif), i.e., the Glu-Ala-Pro-Ser motif consisting of amino acid residues at positions 141-144 of SEQ ID NO: 1, which has an important effect on the anti-angiogenesis activity of ES.

In some embodiments, the sequence of said mutant corresponding to the C motif, i.e. Glu-Ala-Pro-Ser motif consisting of amino acid residues at positions 141-144 of SEQ ID NO: 1, is partially or entirely mutated, which can increase the ATPase activity and

anti-angiogenesis activity of ES.

Preferably, the Glu-Ala-Pro-Ser motif consisting of amino acid residues at positions 141-144 of SEQ ID NO: 1 which corresponds to the C motif is entirely mutated to Asp-Ser-Arg-Ala, which can increase the anti-angiogenesis function of ES.

Preferably, the mutational engineering of the motif corresponding to the C motif in the mutant can be conducted in combination with the mutational engineering of the A and B motifs, so as to further increase the anti-angiogenesis function of ES.

Preferably, applying the following engineering schemes to ES or variants thereof would increase its ATPase activity: (1) keeping the amino acid residues corresponding to the conserved amino acid residues G89, G92, and K95 in the A motif GXXGXXK in SEQ ID NO: 1 unchanged; (2) increasing the spatial conformation flexibility of the peptide corresponding to the A motif by adjusting the variable residues X within the A motif GXXGXXK; (3) adding a Ser or Thr after residue K95 in the classic sequence of the A motif GXXGXXK; (4) adjusting the B motif according to the change in the A motif; (5) partially or entirely mutating the amino acid residues in the C motif; (6) adjusting the C motif according to the change in the B motif; (7) adjusting the C motif according to the change in the A motif; (8) changing the A, B, and C motifs at the same time.

The 8 schemes above can be used alone respectively, and more preferably, the 8 schemes above can be used in combination to obtain better ES mutants with increased ATPase activity.

In detailed embodiments, the ES mutant of the present invention has a sequence selected from the following group: SEQ ID NO: 3-34 and SEQ ID NO: 37-39. Preferably, the endostatin mutant of the present invention has a sequence selected from the following group: SEQ ID NO: 3, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30.

Preferably, the ES mutant of the present invention as described above is human ES mutant.

More preferably, the ES mutant of the present invention as described above comprises a mutation at ATPase binding site.

The present invention also provides a pharmaceutical composition, which comprises an ES mutant of the present invention as described above and a pharmaceutically acceptable carrier. In the pharmaceutical composition of the present invention, said ES mutant can be covalently linked to a polyethylene glycol (PEG) molecule. Preferably, said PEG molecule is monomethoxypolyethylene glycol (mPEG), and the molecular weight of said PEG molecule can be 5-40 kD, such as 5-20 kD, or 20-40 kD, preferably the molecular weight of said PEG molecule is 20 kD, such as a 20 kD monomethoxypolyethylene glycol (mPEG), such as monomethoxy polyethylene glycol propionaldehyde (mPEG-ALD) or monomethoxy polyethylene glycol butyrald (mPEG-Buty).

Preferably, the PEG molecule is covalently linked to the  $\alpha$ -amino group at the N-terminal of said ES mutant.

The pharmaceutical composition of the present invention can be obtained by conventional methods using a pharmaceutically acceptable carrier well known in the art, for example, by formulating it into a powder or an injection.

The term "therapeutically effective amount" as used herein refers to the amount of active compound sufficient to cause the biological or medical response in human body as sought by a clinician. It will be appreciated that the dose will vary depending on the compound used, the mode of administration, the condition of the disease and other factors. A typical daily dose acceptable to a patient may range from 0.01 mg to 100 mg of active ingredient per kg of body weight.

The present invention also provides a method for treating tumor, comprising administering to a tumor patient an ES mutant of the invention or a pharmaceutical composition of the invention as described above. The administration to the subject may be conducted conveniently by a method known to those skilled in the art, such as intravenous injection.

The present invention also provides a method of treating obesity, fatty liver or insulin resistance, comprising administering to a patient suffering from obesity, fatty liver or insulin resistance an ES mutant of the invention or a pharmaceutical composition of the invention as described above.

The present invention also relates to the use of ES mutant as described above in the manufacture of a medicament for the treatment of an angiogenesis-related disease. For example, said angiogenesis-related disease may be tumor, obesity, fatty liver, insulin resistance, and the like.

The present invention also provides a method for increasing the anti-angiogenesis activity of endostatin or variants thereof, by genetic engineering on the A motif and/or the B motif and/or the C motif of endostatin or variants thereof, to obtain an endostatin mutant, the method comprises one or more of the following steps: (1) keeping the amino acid residues corresponding to the conserved amino acid residues G89, G92, and K95 in the A motif GXXGXXK in SEQ ID NO:1 unchanged; (2) increasing the spatial conformation flexibility of the peptide corresponding to the A motif by adjusting the variable residues X within the A motif GXXGXXK; (3) adding a Ser or Thr after residue K95 in the classic sequence of A motif GXXGXXK; (4) adjusting the B motif according to the change in the A motif; (5) partially or entirely mutating the amino acid residues in the C motif; (6) adjusting the C motif according to the change in the B motif; (7) adjusting the C motif according to the change in the A motif; (8) changing the A, B, and C motifs at the same time, wherein said endostatin mutant has a sequence selected from the group consisting of SEQ ID NO: 6-8, SEQ ID NO: 10-21, SEQ ID NO:24 and SEQ ID NO: 37-39; or wherein said endostatin mutant consists of a sequence selected from the group consisting of SEQ ID NO: 4, 5 and 9.

The present invention further provides a mutant of endostatin or variants thereof, wherein said mutant has a sequence selected from the group consisting of SEQ ID NO: 6-8, SEQ ID NO:10-21, SEQ ID NO:24 and SEQ ID NO: 37-39; or wherein said endostatin mutant consists of a sequence selected from the group consisting of SEQ ID NO: 4, 5 and 9.

The present invention further provides a method of inhibiting endothelial cell migration or treating tumor, including administering to a patient an effective amount of an

endostatin mutant consisting of a sequence selected from the group consisting of SEQ ID NO: 3, 6-8, 10-21, 24-34 and 37-39; or an endostatin mutant consisting of a sequence selected from the group consisting of SEQ ID NO: 4, 5 and 9.

Furthermore, the present invention provides for use of the above-described mutants in the preparation of a medicament for treating an angiogenesis-related disease.

### **Brief Description of the Drawings**

Figure 1: expression of ES mutant S03 in engineered bacteria.

Figure 2: purification of ES mutant S03 and its mPEG modified products:

- (A) purification of proteins from inclusion bodies;
- (B) purification of refolded proteins;
- (C) purification of modified proteins;

Figure 3: native human ES sequence, wherein the first amino acid residue M at the N-terminal can be deleted randomly when recombinantly expressed in *Escherichia coli*.

Figure 4: the S03 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 5: the S04 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 6: the S05 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 7: the S06 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 8: the S07 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 9: the S08 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 10: the S11 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 11: the S13 sequence recombinantly expressed by *Escherichia coli*, wherein

the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 12: the S14 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 13: the S15 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 14: the S16 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 15: the S17 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 16: the S18 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 17: the S19 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 18: the S20 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 19: the NSN1 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 20: the NSN2 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 21: the NSN3 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 22: the NSN4 sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 23: the E176A sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 24: the C174E sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 25: the E-M sequence recombinantly expressed by *Escherichia coli*, wherein the first amino acid residue M at the N-terminal can be deleted randomly.

Figure 26: comparison of unmodified ES mutants S03, NSN4 and E-M on the activity of inhibiting migration of endothelial cells.

Figure 27: comparison of ES mutants E176A and C174E on the activity of inhibiting migration of endothelial cells.

Figure 28: comparison of modified ES mutants MS03, MS04, MS05, MS06, MS07, MS08, MS11, and MS13 on the activity of inhibiting migration of endothelial cells.

Figure 29: comparison of modified ES mutants MS03, MS14, MS15, MS16, MS17, MS18, MS19, and MS20 on the activity of inhibiting migration of endothelial cells.

Figure 30: comparison of modified ES mutants MS03, MNSN1, MNSN2, MNSN3 and MNSN4 on the activity of inhibiting migration of endothelial cells.

Figure 31: forward PCR primer sequence for amplification of ES. (SEQ ID NO: 35)

Figure 32: reverse PCR primer sequence for amplification of ES. (SEQ ID NO: 36)

Figure 33: the sequences of ES mutants 36 (SEQ ID NO: 25), 249 (SEQ ID NO: 26), 381 (SEQ ID NO: 27), 57 (SEQ ID NO: 28), 114 (SEQ ID NO: 29), 124 (SEQ ID NO: 30)

and 125 (SEQ ID NO: 31).

Figure 34: the sequences of ES mutants 160 (SEQ ID NO: 32), 163 (SEQ ID NO: 33) and 119 (SEQ ID NO: 34).

Figure 35: comparison of unmodified ES mutants 36, 249, 381 and modified ES mutants M36, M249, M381 on the activity of inhibiting migration of endothelial cells.

Figure 36: comparison of modified ES mutants NSN4, M249, M119, M160, M163, M125, M57, M124 and M114 on the activity of inhibiting migration of endothelial cells.

Figure 37: the sequences of unmodified ES mutants Endu-E-M (SEQ ID NO: 37), Endu-114 (SEQ ID NO: 38) and Endu-57 (SEQ ID NO: 39).

Figure 38: comparison of unmodified ES mutants Endu-E-M, Endu-114 and Endu-57 on the activity of inhibiting migration of endothelial cells.

### **Detailed Description of the Invention**

Unless otherwise indicated, the scientific and technical terms used in this specification should have the meanings that are commonly understood by a skilled person in the art. In general, the names and techniques associated with cellular and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry used in the present specification are well known and commonly used in the art.

Unless otherwise indicated, the methods and techniques used in this specification are generally carried out according to the conventional methods or references cited in this specification.

#### **ES, ES mutants and PEG modified products**

ES (Endostatin) refers to native endostatin, such as human endostatin having the sequence of SEQ ID NO: 1, and when the human ES is recombinantly expressed in *E. coli*, an amino acid residue M will be randomly added to N-terminal of some products (Fig. 3). In the present application, an ES mutant refers to a mutant protein obtained by mutating one or some amino acid residues of an ES variant, such as amino acid deletion, insertion or substitution in an ATP-binding motif. ES mutants can be naturally occurring, for example, when ES is recombinantly expressed in yeast, an ES mutant with an N-terminal deletion of 4 amino acids can be produced due to random deletion at the N-terminal, and furthermore, the C-terminal K can also be randomly deleted. ES mutants can also be artificially constructed, for example, in order to promote protein expression and improve stability, Endu is a mutant produced by adding nine additional amino acid residues MGGSHHHHH to the N-terminal of native ES by genetic engineering means, wherein the first amino acid M can be randomly deleted when recombinantly expressed in *E. coli*, which makes Endu have the sequence of SEQ ID NO: 2.

The unmodified and modified ES and ES mutant proteins in the present invention were all provided by Beijing Protgen Ltd.

Polyethylene glycol (PEG)-modified ES is named M2ES, and PEG-modified ES mutants are named by adding "M" prior to the mutant designation: for example, PEG-modified ES mutant S03 is named MS03 and PEG-modified ES mutant NSN1 is named MNSN1. For example, in some detailed embodiments of the present invention, the molecule named MS03 or MNSN1 may be the product of a mutant called S03 or NSN1 modified by

monomethoxypolyethylene glycol propionaldehyde (mPEG-ALD) with a molecular weight of 20 kD, and the coupling sites are the activated mPEG-ALD aldehyde group and the N-terminal  $\alpha$ -amino group of S03 or NSN1.

ATP-binding motif refers to a typical amino acid sequence that binds to ATP in a protein molecule with ATPase activity. The ATP-binding motif usually has a P-loop structure, and the P-loop structure has the following typical sequences: GXXGXXK, (G/A)XXXXGK(T/S), GXXXXGKS and GXXGXGKS. For human ES, the ATP-binding motif mainly refers to the sequence in a form of GXXGXXK, wherein the amino acid residues which are not substituted by X are more conserved. In general, these ATP-binding motifs can also bind to GTP, UTP, CTP, and the like.

The ATP-binding motifs referred to in the present invention include the A motif (Walker A motif), the B motif (Walker B motif) and the C motif (Walker C motif). The A motif refers to the site with a sequence in the form of GXXGXXK, wherein X is a variable amino acid residue. The A motif is the main site for ES and ATP-binding and catalytic hydrolysis. The B motif refers to the site with sequence in the form of hhhhE, wherein h is a hydrophobic amino acid residue. The B motif is involved in the binding of ATP to ES and affects the ATPase activity of ES by influencing the binding of ES to ATP. The C motif refers to the site with a sequence of Glu-Ala-Pro-Ser (i.e. EAPS) in the ES molecule and is likely to affect the ATPase activity of ES by indirectly influencing the binding of ES with ATP, which needs to be verified by the information of the crystal structure of ES-ATP complex. In addition, since the spatial conformation of a protein is formed by the folding of the peptide chain, the adjacent amino acid residues in the primary sequence are often not close to each other in the spatial conformation; conversely, the amino acid residues far apart in the primary sequence are close to each other in the spatial conformation. The stability of the local conformation of protein molecules is largely dependent on the stability of the overall molecular conformation, and the change of local amino acid sequence may lead to the change of overall molecular conformation. Thus, it will be appreciated by those skilled in the art that there are other sites involved in the regulation of ES and ATP interaction apart from the three motifs of A, B, and C, which can also affect the ATPase activity of ES and inhibit angiogenesis. These sites may play a role alone or in combination with the A, B, C motifs or any combination thereof to influence the ATPase activity of ES and inhibit angiogenesis. Thus, in some embodiments of the present invention, in addition to mutations in the A, B, C motifs or combinations thereof, mutations have been introduced to sites other than the three motifs to achieve better results.

We have found that the ATPase activities of the tested ES, ES variants, ES mutants and their mPEG modified products are positively related to the activity of inhibiting endothelial cell migration, that is, the ES mutants with high activity of inhibiting endothelial cell migration also have high ATPase activity. Based on this finding, in order to obtain ES with high activity of inhibiting endothelial cell migration, we can increase the ATPase activity of ES by amino acid deletion, insertion or substitution in the ATP-binding motifs of ES.

Accordingly, the present invention also provides a method of increasing the activity of ES or its variants of inhibiting angiogenesis and tumor growth, including increasing the ATPase activity of ES or its variants. Specifically, by genetic engineering means, mutations

can be introduced to ES or variants thereof in the A motif GXXGXXK which participates in ATP-binding, or in the A motif and the B motif simultaneously, or in the C motif, or in any combination of the A, B and C motifs to obtain mutants of ES or variants thereof with increased ATPase activity. These mutants have improved biological activities, such as increased activity of inhibiting angiogenesis (such as inhibiting migration of endothelial cells) and increased activity of inhibiting tumor growth. Among them, mutations in the B motif usually lead to decreased activity of inhibiting angiogenesis and tumor growth, so particular attention should be paid to the mutations in the B motif.

Thus, in an example of the present invention, the following mutations were introduced to the A motif or the B motif of ES:

S03 - SEQ ID NO: 3 (Figure 4)  
S04 - SEQ ID NO: 4 (Figure 5)  
S05 - SEQ ID NO: 5 (Figure 6)  
S06 - SEQ ID NO: 6 (Figure 7)  
S07 - SEQ ID NO: 7 (Figure 8)  
S08 - SEQ ID NO: 8 (Figure 9)  
S11 - SEQ ID NO: 9 (Figure 10)  
S13 - SEQ ID NO: 10 (Figure 11)  
S14 - SEQ ID NO: 11 (Figure 12)  
S15 - SEQ ID NO: 12 (Figure 13)  
S16 - SEQ ID NO: 13 (Figure 14)  
S17 - SEQ ID NO: 14 (Figure 15)  
S18 - SEQ ID NO: 15 (Figure 16)  
S19 - SEQ ID NO: 16 (Figure 17)  
S20 - SEQ ID NO: 17 (Figure 18)  
NSN1 - SEQ ID NO: 18 (Figure 19)  
NSN2 - SEQ ID NO: 19 (Figure 20)  
NSN3 - SEQ ID NO: 20 (Figure 21)  
NSN4 - SEQ ID NO: 21 (Figure 22)  
E176A - SEQ ID NO: 22 (Figure 23)  
C174E - SEQ ID NO: 23 (Figure 24)  
E-M-SEQ ID NO: 24 (Figure 25)  
36 - SEQ ID NO: 25 (Figure 33)  
249 - SEQ ID NO: 26 (Figure 33)  
381 - SEQ ID NO: 27 (Figure 33)  
57 - SEQ ID NO: 28 (Figure 33)  
114 - SEQ ID NO: 29 (Figure 33)  
124 - SEQ ID NO: 30 (Figure 33)  
125 - SEQ ID NO: 31 (Figure 33)  
160 - SEQ ID NO: 32 (Figure 34)  
163 - SEQ ID NO: 33 (Figure 34)  
119 - SEQ ID NO: 34 (Figure 34)  
Endu-E-M-SEQ ID NO: 37 (Figure 37)

Endu-57 - SEQ ID NO: 38 (Figure 37)

Endu-114 - SEQ ID NO: 39 (Figure 37)

When ATPase activity was measured by biochemical methods, it was found that ATPase activity of mutants with increased activity of inhibiting endothelial cell migration was significantly higher than that of ES (Table 1).

It was found that the changes in ATPase activity and the activity of inhibiting endothelial cell migration of Endu caused by mutations in ATP-binding motifs were similar to those changes in the ES related activities caused by the same mutations. Therefore, we believe that the method of altering the ATPase activity and the activity of inhibiting endothelial cell migration by mutating ATP-binding motifs in ES is also applicable to ES mutants.

Thus, the present invention also provides ES mutants having an increased activity of inhibiting angiogenesis, wherein the mutants comprise a mutation in their A motif and/or B motif and/or C motif, and the ATPase activity of the mutants is increased compared to the corresponding wild-type ES or variants thereof.

Preferably, the ATPase activity of the ES mutants is increased by at least 100% compared to the wild-type ES, i.e., the ATPase activity of the mutants is 200% of that of the wild-type ES, 300% or more of that of the wild-type ES.

In some embodiments, the mutants comprise mutations in their ATP-binding motifs compared to the corresponding wild-type ES or ES variants. For example, the mutants have mutations in the sequence corresponding to the Gly-Ser-Glu-Gly-Pro-Leu-Lys motif consisting of amino acid residues at positions 89-95 of SEQ ID NO: 1, wherein the mutations are selected from substitution, deletion or addition of one or several amino acid residues, or a combination thereof, which makes the mutants have increased ATPase activity.

Preferably, applying the following engineering schemes to ES or variants thereof would increase its ATPase activity: (1) keeping those corresponding to the conserved amino acid residues G89, G92, and K95 in the A motif GXXGXXK of SEQ ID NO: 1 unchanged; (2) increasing the spatial conformation flexibility of the peptide corresponding to the A motif by adjusting the variable residue X within the A motif GXXGXXK; (3) optionally adding a Ser or Thr after residue K95 in the sequence of classic A motif GXXGXXK; (4) adjusting the B motif according to the change in the A motif; (5) partially or entirely mutating the amino acid residues in the C motif; (6) adjusting the C motif according to the change in the B motif; (7) adjusting the C motif according to the change in the A motif; (8) changing the A, B, and C motifs at the same time.

In detailed embodiments, the ES mutant of the present invention comprises a sequence selected from the following group consisting of: SEQ ID NO: 3-21, and 24. Preferably, the endostatin mutant of the present invention comprises a sequence selected from the following group consisting of: SEQ ID NO: 3, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 24.

Preferably, the ES mutant of the present invention is human ES mutant.

The present invention also provides a method of treating tumor, comprising administering to the patient an effective amount of an endostatin mutant of the present invention as described above or a pharmaceutical composition of the present invention as described above. The angiogenesis-related diseases include tumor, obesity, fatty liver and

insulin resistance. Preferably, the angiogenesis-related disease is tumor.

The present invention is further illustrated by the following non-limiting examples. It is to be understood that the invention is not limited to these examples.

## Examples

### Example 1: Construction of ES recombinant strains

In this example, Endostatin was cloned from the cDNA of human lung cancer cell A549, and ligated into pET30a plasmid. The 5' primer used for gene amplification was GGAATTCCATATGCACAGCCACCGCGACTTC (Figure 31, SEQ ID NO: 35) and the 3' primer was CCGCTCGAGT TACTTGGAGGCAGTCATGAAGCTG (Figure 32, SEQ ID NO: 36). Endonucleases were NdeI and XhoI, respectively.

The recombinant plasmids described above were transformed into *E. coli* according to conventional molecular cloning techniques and expressed.

### Example 2: Construction of ES mutant strains with ATP-binding motif mutations

In this example, the ATP-binding motif of wild-type human ES was subjected to mutational engineering. The upstream and downstream primers and the transformation method were the same as those in Example 1. The mutants' numbers and the changes occurred are as follows:

S03—SEQ ID NO: 3 (Figure 4) four amino acid residues HSHR at the N-terminal were deleted, while the A motif was mutated to be GESGAGK, and T was inserted;

S04—SEQ ID NO: 4 (Figure 5) four amino acid residues HSHR at the N-terminal were deleted, S was inserted after the A motif. At the same time, the E and subsequent amino acid residues NSFMTASK in the B motif were deleted;

S05—SEQ ID NO: 5 (Figure 6) four amino acid residues HSHR at the N-terminal were deleted, T was inserted after the A motif. At the same time, the E and subsequent amino acid residues NSFMTASK in the B motif were deleted;

S06—SEQ ID NO: 6 (Figure 7) four amino acid residues HSHR at the N-terminal were deleted, while the A motif was mutated to be GESGAGK and then T was inserted. At the same time, the E and subsequent amino acid residues NSFMTASK in the B motif were deleted;

S07—SEQ ID NO: 7 (Figure 8) the A motif was mutated to be GESGAGK and T was inserted. At the same time, deleted the C-terminal amino acid residues SFMTASK;

S08—SEQ ID NO: 8 (Figure 9) the A motif was mutated to be GESGAGK and T was inserted. At the same time, the C-terminal amino acid residues TASK were deleted;

S11—SEQ ID NO: 9 (Figure 10) the C-terminal amino acid residues SFMTASK were deleted;

S13—SEQ ID NO: 10 (Figure 11) the N-terminal residues HS were deleted, the A motif was mutated to be GESGAGK and T was inserted. At the same time, the C-terminal SFMTASK were deleted;

S14—SEQ ID NO: 11 (Figure 12) the N-terminal residues HS were deleted, the A motif was mutated to be GESGAGK and T was inserted. At the same time, the C-terminal

TASK were deleted;

S15——SEQ ID NO: 12 (Figure 13) the N-terminal residues HS were deleted, the A motif was mutated to be GESGAGK and T was inserted. At the same time, the C-terminal K was deleted;

S16——SEQ ID NO: 13 (Figure 14) the N-terminal residue H was deleted, the A motif was mutated to be GESGAGK and T was inserted. At the same time, the C-terminal K was deleted;

S17——SEQ ID NO: 14 (Figure 15) the N-terminal residue H was deleted, the A motif was mutated to be GESGAGK and T was inserted. At the same time, the C-terminal SFMTASK were deleted;

S18——SEQ ID NO: 15 (Figure 16) the N-terminal residue H was deleted, the A motif was mutated to be GESGAGK and T was inserted. At the same time, the C-terminal TASK were deleted;

S19——SEQ ID NO: 16 (Figure 17) the N-terminal residue H was deleted, the A motif was mutated to be GESGAGK and T was inserted;

S20——SEQ ID NO: 17 (Figure 18) the N-terminal residues HS were deleted, the A motif was mutated to be GESGAGK and T was inserted;

NSN1——SEQ ID NO: 18 (Figure 19) deleted Ser-88, the A motif was mutated to be GESGAGK and T was inserted;

NSN2——SEQ ID NO: 19 (Figure 20) the A motif was mutated to be GESGAGK, P96T&G97P;

NSN3——SEQ ID NO: 20 (Figure 21) the A motif was mutated to be GESGAGK, P96T;

NSN4——SEQ ID NO: 21 (Figure 22) the A motif was mutated to be GESGAGK, P96T, Gly-98 was inserted;

E176A——SEQ ID NO: 22 (Figure 23) E176A;

C174E——SEQ ID NO: 23 (Figure 24) C174E;

E-M——SEQ ID NO: 24 (Figure 25) the A motif was mutated to be GESGAGK, and T was inserted.

### Example 3: Expression and preparation of recombinant ES and its mutants

In this example, the expression and preparation methods of ES and its mutants are briefly described as follows taking S03 as an example: ES or its mutant engineering strains were spreading cultivated overnight in LB medium shaking flask, inoculated into a 5L fermentor (Sartorius), and IPTG was added timely for induction. After induction, cultivation was continued for about 4 hours, then the bacteria were collected, and analyzed by electrophoresis (Figure 1).

The bacteria cells were resuspended in PBS buffer and were thoroughly crushed with a high-pressure homogenizer, repeatedly for three times, and each time after crushing were centrifuged to collect the sediment, which was then resuspended in PBS buffer. The sediment of crushed bacteria was dissolved in Tris-HCl buffer containing 8 M urea (pH 8.5) and then eluted with DEAE chromatography media (GE Healthcare) with Tris-HCl buffer at pH 8.5. The penetrated fraction was collected and a purified protein before renaturation was

obtained. After refolding the protein, gradient elution was performed using a CM chromatography media (GE Healthcare) with Tris-HCl buffer at pH 8.5 with a salt concentration ranged from 0 to 500 mM NaCl to obtain a refolded protein with a purity greater than 95% (Figure 2A, B). The refolded protein was dialyzed against NaAc-HAc (pH 6.0). Monomethoxypolyethylene glycol propanal (mPEG-ALD, 20 kDa, Beijing JianKai Technology Co., Ltd) with an average molecular weight of 20 kD was used to perform N-terminal single modification of the refolded protein according to the operation method of described in the product specification. The modified product was purified using a SP column (GE Healthcare), gradient elusion was performed using NaCl with a concentration of 0-500 mM to give the target fractions (Figure 2C).

The preparation of other ES mutants and their modified products were the same as described above.

#### Example 4: Assay for ATPase activity of ES, ES mutants and their mPEG modified products

A method for testing ATPase activity disclosed in prior art (PCT/CN2012/081210) was used in this example. The ATPase activity of ES, ES mutants and their mPEG modified products was tested. The results were shown in Table 1. Protein Myosin (extracted from pig heart, Sigma) with relatively high ATPase activity was used as a positive control in this assay.

#### Example 5: Activity of ES and ES mutants to inhibit endothelial cell migration

The Transwell endothelial cell assay disclosed in prior art (PCT/CN2012/081210) was used in this example. The endothelial cells HMEC were divided into the following groups and were treated differently. The first group: negative control group, no ES (the same amount of buffer solution was added) treatment; the second group: ES (20 µg/mL) treatment; the third group: ES mutant YH-16 (20 µg/mL) treatment; the fourth group: ES mutant S03 (20 µg/mL) treatment; the fifth group: ES mutant NSN4 (20 µg/mL) treatment; the sixth group: ES mutant E-M (20 µg/mL) treatment. The results showed that the activity of S03, NSN4 and E-M to inhibit the endothelial cell migration was significantly increased compared to ES. The number of migrated cells of the S03, NSN4 and E-M treatment groups were approximately 30%, 16% and 40% of the ES treatment group, respectively (Figure 26).

The activity of ES mutants E176A and C174E to inhibit endothelial cell migration were tested using the same assay. The activity of E176A and C174E to inhibit endothelial cell migration were both lower than ES (Figure 27).

#### Example 6: Activity of mPEG-modified ES, ES mutants to inhibit endothelial cell migration

The activity of mPEG-modified ES, ES mutants to inhibit endothelial cell migration was tested by the method described in Example 5. Since the increase of the activity of inhibiting endothelial cell migration was significant for many mutant proteins, and in order to reflect the difference in activity between the mutant proteins more clearly, in this example a reduced dose (i.e. 5 µg / mL) was used to treat the cells, and obvious inhibition effect was still able to be observed, as follows:

The activity of mPEG-modified ES mutants MS03, MS04, MS05, MS06, MS07, MS08, MS11, MS13 to inhibit endothelial cell migration (Figure 28). Among them, the

activity of MS03, MS04, MS07, MS11, MS13 to inhibit endothelial cell migration was significantly better than that of M2ES: the number of migrated cells of the MS03 treatment group was about 1/8 of that of the M2ES treatment group, the number of migrated cells of the MS04, MS07, MS11 and MS13 treatment group was about 1/2 of that of the M2ES treatment group; while the activity of MS05, MS06 and MS08 to inhibit endothelial cell migration was lower than that of M2ES.

The activity of mPEG-modified ES mutants MS03, MS14, MS15, MS16, MS17, MS18, MS19, MS20 to inhibit endothelial cell migration (Figure 29). Among them, the activity of MS03, MS14, MS17 to inhibit endothelial cell migration was significantly better than that of M2ES; the activity of MS15, MS19 to inhibit endothelial cell migration had no significant difference with that of M2ES; the activity of MS16, MS18, MS20 to inhibit endothelial cell migration was lower than that of M2ES.

The activity of mPEG-modified ES mutants MS03, MNSN1, MNSN2, MNSN3, MNSN4 to inhibit endothelial cell migration (Figure 30). The activity of MS03, MNSN1, MNSN2, MNSN3 and MNSN4 to inhibit endothelial cell migration was significantly better than that of M2ES, and wherein the number of migrated cells of the MNSN4 treated group was about 1/20 of that of M2ES.

Mutations with increased ATPase activity showed comparable or significantly increased activity of inhibiting endothelial cell migration to that of ES, which is consistent with the positive correlation between the activity of ATPase and the activity of inhibiting endothelial cells migration.

#### Example 7: Construction of ES mutant strains

In this example, mutant engineering was made on wild-type human ES, specific methods, upstream and downstream primers and engineering methods were the same as in Example 1. The mutants' numbers and their sequences are shown in Figure 33 and Figure 34.

36 - SEQ ID NO: 25 (Figure 33) 3 amino acid residues HSH at the N-terminal were deleted, A39Q, and Gly-89 was deleted;

249 - SEQ ID NO: 26 (Figure 33) 3 amino acid residues HSH at the N-terminal were deleted, the A motif was mutated to be GSQGQLQ, the C motif was mutated to be DERG;

381 - SEQ ID NO: 27 (Figure 33) the A motif was mutated to be GSEAPLR;

57 - SEQ ID NO: 28 (Figure 33) the A motif was mutated to be GESGAGK, the C motif was mutated to be DSRA;

114 - SEQ ID NO: 29 (Figure 33) the B motif was mutated to be VLCIA, the C motif was mutated to be DSRA;

124 - SEQ ID NO: 30 (Figure 33) 4 amino acid residues HSHR at the N-terminal were mutated, the A motif was mutated to be GSEGPLR, the C motif was mutated to be DSRA;

125 - SEQ ID NO: 31 (Figure 33) 4 amino acid residues at the N-terminal were mutated, the A motif was mutated to be GSEGPLR, the C motif was mutated to be DSRA, and K was added at the C-terminal;

160 - SEQ ID NO: 32 (Figure 34) amino acid residues other than the A, B, and C

motifs were mutated, see the sequence.

163 - SEQ ID NO: 33 (Figure 34) the A motif was mutated to be GSQGQLQ, the C motif was mutated to be ETTG;

119 - SEQ ID NO: 34 (Figure 34) the A motif was mutated to be VSQGQLQ.

**Example 8: Activity of mPEG-modified ES and ES mutants to inhibit endothelial cell migration**

The activity of mPEG-modified ES and ES mutants to inhibit endothelial cell migration was tested by the method described in Example 6, detailed as follows:

The activity of mPEG-modified ES mutants 36, 249, 381 and modified ES mutants M36, M249, M381 to inhibit endothelial cell migration (Figure 35). Among them, the number of migrated cells in the 36 treatment group was about 70% of that in the ES treatment group. There was no significant difference between the activity of the 249 and 381 group and the activity of the ES group in inhibiting endothelial cells migration; the number of migrated cells in the modified mutant M36 treatment group was about 50% of that in the ES treatment group; There was no significant difference between activity of the M249, M381 group and the activity of the ES group in inhibiting endothelial cells migration.

The activity of mPEG-modified ES mutants NSN4, M249, M119, M160, M163, M125, M57, M124, M114 to inhibit endothelial cell migration (Figure 36). The activity of NSN4, M249, M160, M163, M125, M57, M124, M114 to inhibit endothelial cell migration was significantly increased compared to that of M2ES. M119 had no significant difference compared to M2ES. Among them, the number of migrated cells in the M57, M124 and M114 treated groups was about 34%, 28% and 24% of that in the M2ES treated group respectively.

**Example 9: Construction of ES mutant strains**

In this example, mutational engineering was made on Endu, and the specific methods, upstream and downstream primers and transformation methods were the same as those in Example 1. The mutants' numbers and their sequences are shown in Figure 37.

Endu-E-M - SEQ ID NO: 37 (Figure 37) MGGSHHHHH was added at the N-terminal, the A motif was mutated to GESGAGK, and T was inserted thereafter;

Endu-57 - SEQ ID NO: 38 (Figure 37) MGGSHHHHH was added at the N-terminal, the A motif was mutated to GESGAGK, and T was inserted thereafter;

Endu-114 - SEQ ID NO: 39 (Fig. 37) MGGSHHHHH was added at the N-terminal, the A motif was mutated to GESGAGK, and T was inserted thereafter;

**Example 10: The activity of inhibiting endothelial cell migration of mPEG-modified ES mutants**

The activity of inhibiting endothelial cell migration of mPEG-modified ES mutants Endu-E-M, Endu-57, Endu-114 was tested by the method described in Example 6 (Figure 38).

The activity of inhibiting endothelial cell migration of Endu-E-M, Endu-57 and Endu-114 was significantly better than that of Endu (control), and the inhibition rates were 64%, 50% and 34% respectively.

Table 1

Number	Sample name	ATPase activity (nM/mg/min)	Sample name	ATPase activity (nM/mg/min)
1	ES	14920	mPEG-ES	2596
2	Endu	5586	mPEG-Endu	1626
3	S03	26110	MS03	4585
4	S04	24021	MS04	4057
5	S05	22828	MS05	4269
6	S06	19693	MS06	3474
7	S07	23128	MS07	3987
8	S08	19995	MS08	3571
9	S11	24322	MS11	4286
10	S13	24737	MS13	4275
11	S14	23250	MS14	4051
12	S15	20679	MS15	3520
13	S16	21082	MS16	3780
14	S17	22866	MS17	4011
15	S18	21421	MS18	3716
16	S19	22160	MS19	3874
17	S20	21025	MS20	3652
18	NSN1	23754	MNSN1	4131
19	NSN2	23345	MNSN2	4136
20	NSN3	26605	MNSN3	4869
21	NSN4	31809	MNSN4	5807
22	E176A	5626	ME176A	1012
23	C174E	7809	MC174E	1405
24	E-M	19396	ME-M	3463

**THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:**

1. A method for increasing the anti-angiogenesis activity of endostatin or variants thereof, by genetic engineering on the A motif and/or the B motif and/or the C motif of endostatin or variants thereof, to obtain an endostatin mutant, the method comprises one or more of the following steps: (1) keeping the amino acid residues corresponding to the conserved amino acid residues G89, G92, and K95 in the A motif GXXGXXK in SEQ ID NO:1 unchanged; (2) increasing the spatial conformation flexibility of the peptide corresponding to the A motif by adjusting the variable residues X within the A motif GXXGXXK; (3) adding a Ser or Thr after residue K95 in the classic sequence of A motif GXXGXXK; (4) adjusting the B motif according to the change in the A motif; (5) partially or entirely mutating the amino acid residues in the C motif; (6) adjusting the C motif according to the change in the B motif; (7) adjusting the C motif according to the change in the A motif; (8) changing the A, B, and C motifs at the same time, wherein said endostatin mutant has a sequence selected from the group consisting of SEQ ID NO: 6-8, SEQ ID NO: 10-21, SEQ ID NO:24 and SEQ ID NO: 37-39; or wherein said endostatin mutant consists of a sequence selected from the group consisting of SEQ ID NO: 4, 5 and 9.

2. The method of any one of claim 1, wherein said endostatin mutant has a sequence selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 24.

3. A mutant of endostatin or variants thereof, wherein said mutant has a sequence selected from the group consisting of SEQ ID NO: 6-8, SEQ ID NO:10-21, SEQ ID NO:24 and SEQ ID NO: 37-39; or wherein said endostatin mutant consists of a sequence selected from the group consisting of SEQ ID NO: 4, 5 and 9.

4. The mutant of claim 3, wherein said mutant has a sequence selected from the group consisting of: SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 24.

5. The mutant of claim 3 or claim 4, wherein said mutant is covalently linked to a PEG molecule.

6. The mutant of claim 5, wherein said PEG molecule is of a molecular weight of 5-40 kD.

7. The mutant of claim 5 or claim 6, wherein said PEG molecule is covalently linked to the  $\alpha$ -amino group at the N-terminal of said mutant.

8. The mutant of any one of claims 5 to 7, wherein said PEG molecule is monomethoxypolyethylene glycol.

9. The mutant of claim 8, wherein said monomethoxypolyethylene glycol is monomethoxypolyethylene glycol propionaldehyde (mPEG-ALD) .

10. A pharmaceutical composition which comprises said mutant of any one of claims 3 to 9, and a pharmaceutically acceptable carrier.

11. A method of inhibiting endothelial cell migration or treating tumor, including administering to a patient an effective amount of an endostatin mutant consisting of a

sequence selected from the group consisting of SEQ ID NO: 3, 6-8, 10-21, 24-34 and 37-39; or an endostatin mutant consisting of a sequence selected from the group consisting of SEQ ID NO: 4, 5 and 9.

12. The method of any one of claims 1, 2 or 11, wherein said endostatin mutant is covalently linked to a PEG molecule.

13. The method of claim 12, wherein said PEG molecule is of a molecular weight of 5-40 kD.

14. The method of claim 12 or 13, wherein said PEG molecule is covalently linked to the  $\alpha$ -amino group at the N-terminal of said mutant.

15. The method of any one of claims 12 to 14, wherein said PEG molecule is monomethoxypolyethylene glycol.

16. The method of claim 15, wherein said monomethoxypolyethylene glycol is monomethoxypolyethylene glycol propionaldehyde (mPEG-ALD) .

17. Use of the mutant of any one of claims 3 to 9 in the preparation of a medicament for treating an angiogenesis-related disease.

18. The use of claim 17, wherein said angiogenesis-related disease is tumor, obesity, fatty liver, or insulin resistance.






Figure 1




Loading Penetration Elution M

(A)



M Loading 150 300 500 mM NaCl

(B)



(C)  
Figure 2

**(M) HSHRDFQPVLHLVALNSPLSGGMR  
GIRGADFQCFQQARAVGLAGTFRAFLS  
SRLQDLYSIVRRADRAAVPIVNLKDELL  
FPSWEALFSGSEGPLKPGARIFSFDGKD  
VLRHPTWPQKSVWHGSDPNGRRLTES  
YCETWRTEAPSATGQASSLLGGRLLGQ  
SAASCHHAYIVLCIENSFMTASK**

Figure 3

**(M) DFQPVLHLVALNSPLSGGMRGIRGA  
DFQCFQQARAVGLAGTFRAFLSSRLQD  
LYSIVRRADRAAVPIVNLKDELLFPSWE  
ALFSGESGAGKTPGARIFSFDGKDVLRH  
PTWPQKSVWHGSDPNGRRLTESYCET  
WRTEAPSATGQASSLLGGRLLGQSAAS  
CHHAYIVLCIENSFMTASK**

Figure 4

**(M) DFQPVLHLVALNSPLSGGMRGIRGA  
DFQCFQQARAVGLAGTFRAFLSSRLQD  
LYSIVRRADRAAVPIVNLKDELLFPSWE  
ALFSGSEGPLKSPGARIFSFDGKDVLRH  
PTWPQKSVWHGSDPNGRRLTESYCET  
WRTEAPSATGQASSLLGGRLLGQSAAS  
CHHAYIVLCI**

Figure 5

**(M)** DFQPVLHLVALNSPLSGGMRGIRGA  
DFQCFQQARAVGLAGTFRAFLSSRLQD  
LYSIVRADRAAVPIVNLKDELLFPSWE  
ALFSGSEGPLKTPGARIFSFDGKDVLRH  
PTWPQKSVWHGSDPNGRRLTESYCET  
WRTEAPSATGQASSLLGGRLLGQSAAS  
CHHAYIVLCI

Figure 6

**(M)** DFQPVLHLVALNSPLSGGMRGIRGA  
DFQCFQQARAVGLAGTFRAFLSSRLQD  
LYSIVRADRAAVPIVNLKDELLFPSWE  
ALFSGESGAGKTPGARIFSFDGKDVLRH  
PTWPQKSVWHGSDPNGRRLTESYCET  
WRTEAPSATGQASSLLGGRLLGQSAAS  
CHHAYIVLCI

Figure 7

**(M)** HSHRDFQPVLHLVALNSPLSGGMR  
GIRGADFCFQQARAVGLAGTFRAFLS  
SRLQDLYSIVRADRAAVPIVNLKDELL  
FPSWEALFSGESGAGKTPGARIFSFDGK  
DVLRHPTWPQKSVWHGSDPNGRRLTE  
SYCETWRTEAPSATGQASSLLGGRLLG  
QSAASCHHAYIVLCIEN

Figure 8

**(M) HSHRDFQPVLHLVALNSPLSGGMR  
GIRGADFCFQQARAVGLAGTFRAFLS  
SRLQDLYSIVRRADRAAVPIVNLKDELL  
FPSWEALFSGESGAGKTPGARIFSFDGK  
DVLRHPTWPQKSVWHGSDPNGRRLTE  
SYCETWRTEAPSATGQASSLLGGRLLG  
QSAASCHHAYIVLCIENSFM**

Figure 9

**(M) HSHRDFQPVLHLVALNSPLSGGMR  
GIRGADFCFQQARAVGLAGTFRAFLS  
SRLQDLYSIVRRADRAAVPIVNLKDELL  
FPSWEALFSGSEGPLKPGARIFSFDGKD  
VLRHPTWPQKSVWHGSDPNGRRLTES  
YCETWRTEAPSATGQASSLLGGRLLGQ  
SAASCHHAYIVLCIEN**

Figure 10

**(M) HRDFQPVLHLVALNSPLSGGMRGIR  
GADFCFQQARAVGLAGTFRAFLSSRL  
QDLYSIVRRADRAAVPIVNLKDELLFPS  
WEALFSGESGAGKTPGARIFSFDGKD  
LRHPTWPQKSVWHGSDPNGRRLTESY  
CETWRTEAPSATGQASSLLGGRLLGQS  
AASCHHAYIVLCIEN**

Figure 11

(M) HRDFQPVLHLVALNSPLSGGMRGIR  
GADFQCFQQARAVGLAGTFRAFLSSRL  
QDLYSIVRRADRAAVPIVNLKDELLFPS  
WEALFSGESGAGKTPGARIFSFDGKD  
LRHPTWPQKSVWHGSDPNGRRLTESY  
CETWRTEAPSATGQASSLLGGRLLGQS  
AASCHHAYIVLCIENSFM

Figure 12

(M) HRDFQPVLHLVALNSPLSGGMRGIR  
GADFQCFQQARAVGLAGTFRAFLSSRL  
QDLYSIVRRADRAAVPIVNLKDELLFPS  
WEALFSGESGAGKTPGARIFSFDGKD  
LRHPTWPQKSVWHGSDPNGRRLTESY  
CETWRTEAPSATGQASSLLGGRLLGQS  
AASCHHAYIVLCIENSFM  
TAS

Figure 13

(M) SHRDFQPVLHLVALNSPLSGGMRGIR  
RGADFQCFQQARAVGLAGTFRAFLSSR  
LQDLYSIVRRADRAAVPIVNLKDELLFP  
SWEALFSGESGAGKTPGARIFSFDGKD  
VLRHPTWPQKSVWHGSDPNGRRLTES  
YCETWRTEAPSATGQASSLLGGRLLGQ  
SAASCHHAYIVLCIENSFM  
TAS

Figure 14

(M)SHRDFQPVLHLVALNSPLSGGMRGIRGADFCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRADRAAVPIVNLKDELLFPSWEALFSGESGAGKTPGARIFSFDGKDVLRHPTWPQKSVWHGSDPNGRRLTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIEN

Figure 15

(M)SHRDFQPVLHLVALNSPLSGGMRGIRGADFCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRADRAAVPIVNLKDELLFPSWEALFSGESGAGKTPGARIFSFDGKDVLRHPTWPQKSVWHGSDPNGRRLTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFM

Figure 16

(M)SHRDFQPVLHLVALNSPLSGGMRGIRGADFCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRADRAAVPIVNLKDELLFPSWEALFSGESGAGKTPGARIFSFDGKDVLRHPTWPQKSVWHGSDPNGRRLTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFM TASK

Figure 17

(M) H R D F Q P V L H L V A L N S P L S G G M R G I R G A D F Q C F Q Q A R A V G L A G T F R A F L S S R L Q D L Y S I V R R A D R A A V P I V N L K D E L L F P S W E A L F S G E S G A G K T P G A R I F S F D G K D V L R H P T W P Q K S V W H G S D P N G R R L T E S Y C E T W R T E A P S A T G Q A S S L L G G R L L G Q S A A S C H H A Y I V L C I E N S F M T A S K

Figure 18

(M) H S H R D F Q P V L H L V A L N S P L S G G M R G I R G A D F Q C F Q Q A R A V G L A G T F R A F L S S R L Q D L Y S I V R R A D R A A V P I V N L K D E L L F P S W E A L F G E S G A G K T P G A R I F S F D G K D V L R H P T W P Q K S V W H G S D P N G R R L T E S Y C E T W R T E A P S A T G Q A S S L L G G R L L G Q S A A S C H H A Y I V L C I E N S F M T A S K

Figure 19

(M) H S H R D F Q P V L H L V A L N S P L S G G M R G I R G A D F Q C F Q Q A R A V G L A G T F R A F L S S R L Q D L Y S I V R R A D R A A V P I V N L K D E L L F P S W E A L F S G E S G A G K T P A R I F S F D G K D V L R H P T W P Q K S V W H G S D P N G R R L T E S Y C E T W R T E A P S A T G Q A S S L L G G R L L G Q S A A S C H H A Y I V L C I E N S F M T A S K

Figure 20

(M) HSHRDFQPVLHLVALNSPLSGGMR  
GIRGADFCFQQARAVGLAGTFRAFLS  
SRLQDLYSIVRRADRAAVPIVNLKDELL  
FPSWEALFSGESGAGKTGARIFSFDGK  
DVLRHPTWPQKSVWHGSDPNGRRLTE  
SYCETWRTEAPSATGQASSLLGGRLLG  
QSAASCHHAYIVLCIENSFMTASK

Figure 21

(M) HSHRDFQPVLHLVALNSPLSGGMR  
GIRGADFCFQQARAVGLAGTFRAFLS  
SRLQDLYSIVRRADRAAVPIVNLKDELL  
FPSWEALFSGESGAGKTGGARIFSFDG  
KDVLRHPTWPQKSVWHGSDPNGRRLT  
ESYCETWRTEAPSATGQASSLLGGRLL  
GQSAASCHHAYIVLCIENSFMTASK

Figure 22

(M) HSHRDFQPVLHLVALNSPLSGGMR  
GIRGADFCFQQARAVGLAGTFRAFLS  
SRLQDLYSIVRRADRAAVPIVNLKDELL  
FPSWEALFSGSEGPLKPGARIFSFDGKD  
VLRHPTWPQKSVWHGSDPNGRRLTES  
YCETWRTEAPSATGQASSLLGGRLLGQ  
SAASCHHAYIVLCIANSFMTASK

Figure 23

**(M)** HSHRDFQPVLHLVALNSPLSGGMR  
 GIRGADFQCFQQARAVGLAGTFRAFLS  
 SRLQDLYSIVRRADRAAVPIVNLKDELL  
 FPSWEALFSGSEGPLKPGARIFSFDGKD  
 VLRHPTWPQKSVWHGSDPNGRRLTES  
 YCETWRTEAPSATGQASSLLGGRLLGQ  
 SAASCHHAYIVLEIENSFMTASK

Figure 24

**(M)** HSHRDFQPVLHLVALNSPLSGGMR  
 GIRGADFQCFQQARAVGLAGTFRAFLS  
 SRLQDLYSIVRRADRAAVPIVNLKDELL  
 FPSWEALFSGESGAGKTPGARIFSFDGK  
 DVLRHPTWPQKSVWHGSDPNGRRLTE  
 SYCETWRTEAPSATGQASSLLGGRLLG  
 QSAASCHHAYIVLCIENSFMTASK

Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30

GGAATTCCATATGCACAGCCACCGCGACTTC

Figure 31

CCGCTCGAGTTACTTGGAGGCAGTCATGAAGCTG

Figure 32

36

(M)RDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARQVGLAGTFRAFLSSRLQDLYSIVRR  
ADRAAVPIVNLKDELLFPSWEALFSSEGPLKPGARIFSFDBGKDVLRHPTWPQKSVWHGSDPNG  
RRLTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTASK

249

(M)RDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRR  
ADRGSPIVNLKDEVLSPSWDSLFSGSQGQLQPGARIFSFDBGDRDILQDSAWPQKSVWHGSDA  
KGRRLPESYCEAWRTDERGTSGQASSLLSGRLLEQKAASCHNSYIVLCIENSFMTASK

381

(M)HVHQDFQPALHLVALNTPLSGGMRGIRGADFQCFQQARQVGLAGTFRAFLSSRLQDLYSI  
VRRADRTAVPIVNLRDEVLFSNWEALFTGSEAPLAGARIFSFDBGDRDVLRHPTWPQKSVWHG  
SDPNGRRLTESYCETWRTEAPSATGQASSLLAGRILLEQKAAGCHNAFIVLCIENSFMTSSK

57

(M)HTHQDFHPVLHLVALNTPLSGGMRGIRGADFQCFQQARAVGLSGTFRAFLSSRLQDLYSI  
VRRADRAAVPIVNLKDELLFPSWEALFGESGAGKTGGARIFSFDBGDRDVLRHPAWPQKSVWH  
GSDPSGRRLTESYCETWRTDSRAATGQASSLLAGRILLEQKAAGCHNAFIVLCIENSFMTSSK

114

(M)HSHRDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSI  
VRRADRAAVPIVNLKDELLFPSWEALFGSEGPLKPGARIFSFDBGDRDVLRHPTWPQKSVWHGS  
DPSGHLTESYCETWRTDSRAATGQASSLLGGRLLGQSAASCHHAYIVLCIANSFMTASK

124

(M)DFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRA  
DRAAVPIVNLKDELLFPSWEALFGSEGPLRPGARIFSFDBGKDVLRHPTLPQKSVWHGSDPSG  
RRLTESYCETWRTDSRAATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTASK

125

(M)DFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRA  
DRAAVPIVNLKDELLFPSWEALFGSEGPLRPGARIFSFDBGKDVLRHPTLPQKSVWHGSDPSG  
RRLTESYCETWRTDSRAATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTASKK

Figure 33

160

(M)HTHQDFHPVLHLVALNTPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSI  
 VRRADRAAVPIVNLKDELLFPSWEALFSGSEGPKPGARIFSFDFGRDILQDSAWPQKSVWHGS  
 DPNGRRLTESYCETWRTEAPSATGQASSLSSGKLLEQSVSSCQHAFVVLCIENSFMTAAKK

163

(M)TPTWYPRMLRVAALNEPSTGDLQGIRGADFQCFQQARAVGLSGTFRAFLSSRLQDLYSIV  
 RRADRAAVPIVNLKDEVLSPSWDSLFSGSQGQLQPGARIFSFDFGRDILQDSAWPQKSVWHGS  
 DPSGRRLMESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTNNRK

119

(M)HTHTSGPGLHLIALNSPQVGNMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIV  
 RRADRSSVPIVNLKDEVLSPSWDSLFSVSQGQLQPGARIFSFDFGRDILQDSAWPQKSVWHGS  
 DPNGRRLTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTASK

Figure 34




Figure 35




Figure 36

Endu-E-M

MGGSHHHHHHSHRDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRR  
 ADRAAVPIVNLKDELLFPSWEALFSGESGAGKTPGARIFSFDFGKDVLRHPTWPQKSVWHGSDPONGRRLTESYC  
 ETWRTEAPSATGQASSLLGGRLLGQSAASCHAYIVLCIENSFMTASK

Endu-114

MGGSHHHHHHSHRDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRR  
 ADRAAVPIVNLKDELLFPSWEALFSGSEGPLKPGARIFSFDFGRDVLRHPTWPQKSVWHGSDPSGHRLTESYCET  
 WRTDSRAATGQASSLLGGRLLGQSAASCHAYIVLCIANSFMTASK

Endu-57

MGGSHHHHHHHTHQDFHPVLHLVALNTPLSGGMRGIRGADFQCFQQARAVGLSGTFRAFLSSRLQDLYSIVRR  
 ADRAAVPIVNLKDELLFPSWEALFSGESGAGKTGGARIFSFDFGRDVLRHPAWPQKSVWHGSDPSGRRLTESYC  
 ETWRTDSRAATGQASSLLAGRRLLEQKAAGCHNAFIVLCIENSFMTSSSK

Figure 37




Figure 38

<110> Çå»<sup>a</sup> óÑ§  
±±¾©ÆØÄþ¾<sup>a</sup>ÉúÙí ÐÆ¾¾· ¢Ø¹ØÐÍ Þ¹ «È¾

<120> Ø»ØØØØ×éµ°°×ØÈØ©Ùí µÄ· Ø×ØÈè¾Æ

<130> 0120-PCT

<160> 39

<170> PatentIn version 3.5

<210> 1

<211> 183

<212> PRT

<213> Homo sapiens

<400> 1

His Ser His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln  
20 25 30

Cys Phe Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Glu Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn  
165 170 175

Ser Phe Met Thr Ala Ser Lys  
180

0120PCT--000001

<210> 2  
<211> 192  
<212> PRT  
<213> ÈÈ¹¤ÐòÁÐ

<220>  
<223> Í »±äÌ å

<400> 2

Met Gl y Gl y Ser His His His His His His Ser His Arg Asp Phe Gl n  
1 5 10 15

Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser Gl y Gl y Met  
20 25 30

Arg Gl y Ile Arg Gl y Ala Asp Phe Gl n Cys Phe Gl n Gl n Ala Arg Ala  
35 40 45

Val Gl y Leu Ala Gl y Thr Phe Arg Ala Phe Leu Ser Ser Arg Leu Gl n  
50 55 60

Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala Val Pro Ile  
65 70 75 80

Val Asn Leu Lys Asp Gl u Leu Leu Phe Pro Ser Trp Gl u Ala Leu Phe  
85 90 95

Ser Gl y Ser Gl u Gl y Pro Leu Lys Pro Gl y Ala Arg Ile Phe Ser Phe  
100 105 110

Asp Gl y Lys Asp Val Leu Arg His Pro Thr Trp Pro Gl n Lys Ser Val  
115 120 125

Trp His Gl y Ser Asp Pro Asn Gl y Arg Arg Leu Thr Gl u Ser Tyr Cys  
130 135 140

Gl u Thr Trp Arg Thr Gl u Ala Pro Ser Ala Thr Gl y Gl n Ala Ser Ser  
145 150 155 160

Leu Leu Gl y Gl y Arg Leu Leu Gl y Gl n Ser Ala Ala Ser Cys His His  
165 170 175

Al a Tyr Ile Val Leu Cys Ile Gl u Asn Ser Phe Met Thr Ala Ser Lys  
180 185 190

<210> 3  
<211> 180  
<212> PRT  
<213> ÈÈ¹¤ÐòÁÐ

<220>  
<223> Í »±äÌ å

<400> 3

0120PCT--000001

Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser  
1 5 10 15

Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe Gln Gln  
20 25 30

Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser Ser  
35 40 45

Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala  
50 55 60

Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser Trp Glu  
65 70 75 80

Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr Pro Gln Ala Arg  
85 90 95

Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr Trp Pro  
100 105 110

Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gln Arg Arg Leu Thr  
115 120 125

Glu Ser Tyr Cys Glu Thr Trp Arg Thr Gln Ala Pro Ser Ala Thr Gln  
130 135 140

Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser Ala Ala  
145 150 155 160

Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Gln Asn Ser Phe Met  
165 170 175

Thr Ala Ser Lys  
180

<210> 4

<211> 171

<212> PRT

<213> ÈE¹¤ÐòÅÐ

<220>

<223> Í »±äÌ å

<400> 4

Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser  
1 5 10 15

Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe Gln Gln  
20 25 30

Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser Ser  
35 40 45

Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala  
50 55 60

Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser Trp Glu  
65 70 75 80

Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Ser Pro Gly Ala Arg  
85 90 95

Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr Trp Pro  
100 105 110

Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg Arg Leu Thr  
115 120 125

Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser Ala Thr Gly  
130 135 140

Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser Ala Ala  
145 150 155 160

Ser Cys His His Ala Tyr Ile Val Leu Cys Ile  
165 170

<210> 5

<211> 171

<212> PRT

<213> EEE<sup>1</sup>xDxD

<220>

<223> f »±äl å

<400> 5

Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser  
1 5 10 15

Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe Gln Gln  
20 25 30

Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser Ser  
35 40 45

Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala  
50 55 60

Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser Trp Glu  
65 70 75 80

Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Thr Pro Gly Ala Arg  
85 90 95

0120PCT--000001

Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr Trp Pro  
100 105 110

Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg Arg Leu Thr  
115 120 125

Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser Ala Thr Gly  
130 135 140

Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser Ala Ala  
145 150 155 160

Ser Cys His His Ala Tyr Ile Val Leu Cys Ile  
165 170

<210> 6

<211> 171

<212> PRT

<213> EE<sup>1</sup>¤ÐòÁÐ

<220>

<223> I »±äl å

<400> 6

Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser  
1 5 10 15

Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe Gln Gln  
20 25 30

Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser Ser  
35 40 45

Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala  
50 55 60

Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser Trp Glu  
65 70 75 80

Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr Pro Gly Ala Arg  
85 90 95

Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr Trp Pro  
100 105 110

Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg Arg Leu Thr  
115 120 125

Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser Ala Thr Gly  
130 135 140

Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser Ala Ala  
145 150 155 160

Ser Cys His His Ala Tyr Ile Val Leu Cys Ile  
165 170

<210> 7  
<211> 177  
<212> PRT  
<213> EE<sup>1</sup>xDxD

<220>  
<223> f »±äl å

<400> 7

His Ser His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gln Ile Arg Gly Ala Asp Phe Gln  
20 25 30

Cys Phe Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr  
85 90 95

Pro Gly Ala Arg Ile Phe Ser Phe Asp Gln Lys Asp Val Leu Arg His  
100 105 110

Pro Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Glu  
115 120 125

Arg Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro  
130 135 140

Ser Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Glu  
145 150 155 160

Gln Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu  
165 170 175

Asn

<210> 8  
<211> 180  
<212> PRT  
<213> EE<sup>1</sup>xDxD

0120PCT--000001

<220>

<223> I »±äl å

<400> 8

His Ser His Arg Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu  
20 25 30

Cys Phe Glu Glu Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr  
85 90 95

Pro Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His  
100 105 110

Pro Thr Trp Pro Glu Lys Ser Val Trp His Gly Ser Asp Pro Asn Glu  
115 120 125

Arg Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro  
130 135 140

Ser Ala Thr Gly Glu Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly  
145 150 155 160

Glu Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu  
165 170 175

Asn Ser Phe Met  
180

<210> 9

<211> 176

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>

<223> I »±äl å

<400> 9

His Ser His Arg Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

0120PCT--000001

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu  
20 25 30

Cys Phe Glu Glu Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Glu Lys Ser Val Trp His Gly Ser Asp Pro Asn Glu Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Glu Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Glu  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn  
165 170 175

<210> 10

<211> 175

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>

<223> f »±äl å

<400> 10

His Arg Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn Ser Pro  
1 5 10 15

Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu Cys Phe  
20 25 30

Glu Glu Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu  
35 40 45

Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg  
50 55 60

Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser  
65 70 75 80

0120PCT--000001

Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr Pro Gly  
85 90 95

Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr  
100 105 110

Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg Arg  
115 120 125

Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser Ala  
130 135 140

Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser  
145 150 155 160

Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn  
165 170 175

<210> 11

<211> 178

<212> PRT

<213> ËÉ¹¤ÐòÁÐ

<220>

<223> f »±äl å

<400> 11

His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro  
1 5 10 15

Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe  
20 25 30

Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu  
35 40 45

Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg  
50 55 60

Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser  
65 70 75 80

Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr Pro Gly  
85 90 95

Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr  
100 105 110

Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg Arg  
115 120 125

0120PCT--000001

Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser Ala  
130 135 140

Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser  
145 150 155 160

Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn Ser  
165 170 175

Phe Met

<210> 12

<211> 181

<212> PRT

<213> EE<sup>1</sup>¤ÐoÁÐ

<220>

<223> f »±äl å

<400> 12

His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro  
1 5 10 15

Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe  
20 25 30

Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu  
35 40 45

Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg  
50 55 60

Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser  
65 70 75 80

Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr Pro Gly  
85 90 95

Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr  
100 105 110

Trp Pro Gln Lys Ser Val Trp His Glu Ser Asp Pro Asn Gly Arg Arg  
115 120 125

Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser Ala  
130 135 140

Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser  
145 150 155 160

Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn Ser  
165 170 175

Phe Met Thr Al a Ser  
180

<210> 13  
<211> 182  
<212> PRT  
<213> EEE<sup>1</sup>xDxD

<220>  
<223> f »±äl å

<400> 13

Ser His Arg Asp Phe Gl n Pro Val Leu His Leu Val Al a Leu Asn Ser  
1 5 10 15

Pro Leu Ser Gl y Gl y Met Arg Gl y Ile Arg Gl y Al a Asp Phe Gl n Cys  
20 25 30

Phe Gl n Gl n Al a Arg Al a Val Gl y Leu Al a Gl y Thr Phe Arg Al a Phe  
35 40 45

Leu Ser Ser Arg Leu Gl n Asp Leu Tyr Ser Ile Val Arg Arg Al a Asp  
50 55 60

Arg Al a Al a Val Pro Ile Val Asn Leu Lys Asp Gl u Leu Leu Phe Pro  
65 70 75 80

Ser Trp Gl u Al a Leu Phe Ser Gl y Gl u Ser Gl y Al a Gl y Lys Thr Pro  
85 90 95

Gl y Al a Arg Ile Phe Ser Phe Asp Gl y Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Gl n Lys Ser Val Trp His Gl y Ser Asp Pro Asn Gl y Arg  
115 120 125

Arg Leu Thr Gl u Ser Tyr Cys Gl u Thr Trp Arg Thr Gl u Al a Pro Ser  
130 135 140

Al a Thr Gl y Gl n Al a Ser Ser Leu Leu Gl y Gl y Arg Leu Leu Gl y Gl n  
145 150 155 160

Ser Al a Al a Ser Cys His His Al a Tyr Ile Val Leu Cys Ile Gl u Asn  
165 170 175

Ser Phe Met Thr Al a Ser  
180

<210> 14  
<211> 176  
<212> PRT  
<213> EEE<sup>1</sup>xDxD

0120PCT--000001

<220>

<223> f »±äl å

<400> 14

Ser His Arg Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn Ser  
1 5 10 15

Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu Cys  
20 25 30

Phe Glu Glu Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe  
35 40 45

Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp  
50 55 60

Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro  
65 70 75 80

Ser Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Glu Lys Ser Val Trp His Gly Ser Asp Pro Asn Glu Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Glu Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Glu  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn  
165 170 175

<210> 15

<211> 179

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>

<223> f »±äl å

<400> 15

Ser His Arg Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn Ser  
1 5 10 15

Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu Cys  
20 25 30

0120PCT--000001

Phe Glu Glu Ala Arg Ala Val Glu Leu Ala Glu Thr Phe Arg Ala Phe  
35 40 45

Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp  
50 55 60

Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro  
65 70 75 80

Ser Trp Glu Ala Leu Phe Ser Glu Glu Ser Glu Ala Glu Lys Thr Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Glu Lys Ser Val Trp His Glu Ser Asp Pro Asn Glu Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Glu Glu Ala Ser Ser Leu Leu Glu Glu Arg Leu Leu Glu Glu  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn  
165 170 175

Ser Phe Met

<210> 16

<211> 183

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>

<223> f »±äl å

<400> 16

Ser His Arg Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn Ser  
1 5 10 15

Pro Leu Ser Glu Glu Met Arg Glu Ile Arg Glu Ala Asp Phe Glu Cys  
20 25 30

Phe Glu Glu Ala Arg Ala Val Glu Leu Ala Glu Thr Phe Arg Ala Phe  
35 40 45

Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp  
50 55 60

Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro  
65 70 75 80

0120PCT--000001

Ser Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn  
165 170 175

Ser Phe Met Thr Ala Ser Lys  
180

<210> 17

<211> 182

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>

<223> f »±äl å

<400> 17

His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro  
1 5 10 15

Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe  
20 25 30

Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu  
35 40 45

Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg  
50 55 60

Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser  
65 70 75 80

Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr Pro Gly  
85 90 95

Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr  
100 105 110

0120PCT--000001

Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg Arg  
115 120 125

Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser Ala  
130 135 140

Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser  
145 150 155 160

Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn Ser  
165 170 175

Phe Met Thr Ala Ser Lys  
180

<210> 18

<211> 183

<212> PRT

<213> EÉ¹¤ÐòÁÐ

<220>

<223> f »±äl å

<400> 18

His Ser His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln  
20 25 30

Cys Phe Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Gly Gln Ser Gly Ala Gly Lys Thr Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gln Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Gln Lys Ser Val Trp His Gln Ser Asp Pro Asn Gln Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn  
 165 170 175

Ser Phe Met Thr Ala Ser Lys  
 180

<210> 19  
 <211> 183  
 <212> PRT  
 <213> EE<sup>1</sup>¤ÐòÅÐ

<220>  
 <223> f »±äl å

<400> 19

His Ser His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn  
 1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln  
 20 25 30

Cys Phe Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
 35 40 45

Phe Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala  
 50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
 65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr  
 85 90 95

Pro Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
 100 105 110

Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Glu Arg  
 115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
 130 135 140

Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln  
 145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn  
 165 170 175

Ser Phe Met Thr Ala Ser Lys  
 180

0120PCT--000001

<210> 20  
<211> 183  
<212> PRT  
<213> ÈÈ¹¤ÐòÁÐ

<220>  
<223> Í »±äÌ å

<400> 20

His Ser His Arg Asp Phe Gl n Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gl n  
20 25 30

Cys Phe Gl n Gl n Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Gl n Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Gl u Leu Leu Phe  
65 70 75 80

Pro Ser Trp Gl u Ala Leu Phe Ser Gly Gl u Ser Gly Ala Gly Lys Thr  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Gl n Lys Ser Val Trp His Gly Ser Asp Pro Asn Gl y Arg  
115 120 125

Arg Leu Thr Gl u Ser Tyr Cys Gl u Thr Trp Arg Thr Gl u Ala Pro Ser  
130 135 140

Ala Thr Gly Gl n Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gl y Gl n  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Gl u Asn  
165 170 175

Ser Phe Met Thr Ala Ser Lys  
180

<210> 21  
<211> 184  
<212> PRT  
<213> ÈÈ¹¤ÐòÁÐ

<220>  
<223> Í »±äÌ å

<400> 21

0120PCT--000001

His Ser His Arg Asp Phe Gl n Pro Val Leu His Leu Val Al a Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Al a Asp Phe Gl n  
20 25 30

Cys Phe Gl n Gl n Al a Arg Al a Val Gly Leu Al a Gly Thr Phe Arg Al a  
35 40 45

Phe Leu Ser Ser Arg Leu Gl n Asp Leu Tyr Ser Ile Val Arg Arg Al a  
50 55 60

Asp Arg Al a Al a Val Pro Ile Val Asn Leu Lys Asp Gl u Leu Leu Phe  
65 70 75 80

Pro Ser Trp Gl u Al a Leu Phe Ser Gly Gl u Ser Gly Al a Gly Lys Thr  
85 90 95

Gly Gly Al a Arg Ile Phe Ser Phe Asp Gl y Lys Asp Val Leu Arg His  
100 105 110

Pro Thr Trp Pro Gl n Lys Ser Val Trp His Gl y Ser Asp Pro Asn Gl y  
115 120 125

Arg Arg Leu Thr Gl u Ser Tyr Cys Gl u Thr Trp Arg Thr Gl u Al a Pro  
130 135 140

Ser Al a Thr Gl y Gl n Al a Ser Ser Leu Leu Gl y Gl y Arg Leu Leu Gl y  
145 150 155 160

Gl n Ser Al a Al a Ser Cys His His Al a Tyr Ile Val Leu Cys Ile Gl u  
165 170 175

Asn Ser Phe Met Thr Al a Ser Lys  
180

<210> 22

<211> 183

<212> PRT

<213> ÈE¹¤ÐòÅÐ

<220>

<223> f »±äl å

<400> 22

His Ser His Arg Asp Phe Gl n Pro Val Leu His Leu Val Al a Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Al a Asp Phe Gl n  
20 25 30

Cys Phe Gl n Gl n Al a Arg Al a Val Gly Leu Al a Gly Thr Phe Arg Al a  
35 40 45

0120PCT--000001

Phe Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Glu Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Glu Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Glu  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Ala Asn  
165 170 175

Ser Phe Met Thr Ala Ser Lys  
180

<210> 23

<211> 183

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>

<223> f »±äl å

<400> 23

His Ser His Arg Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu  
20 25 30

Cys Phe Glu Glu Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

0120PCT--000001

Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Glu Ile Glu Asn  
165 170 175

Ser Phe Met Thr Ala Ser Lys  
180

<210> 24

<211> 184

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>

<223> Í »±äÌå

<400> 24

His Ser His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln  
20 25 30

Cys Phe Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr  
85 90 95

Pro Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His  
100 105 110

Pro Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly  
115 120 125

0120PCT--000001

Arg Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro  
130 135 140

Ser Ala Thr Gly Glu Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly  
145 150 155 160

Gln Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu  
165 170 175

Asn Ser Phe Met Thr Ala Ser Lys  
180

<210> 25

<211> 179

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>

<223> f »±äl å

<400> 25

Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu  
1 5 10 15

Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe Gln  
20 25 30

Gln Ala Arg Gln Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser  
35 40 45

Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala  
50 55 60

Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser Trp  
65 70 75 80

Gl u Ala Leu Phe Ser Ser Glu Gly Pro Leu Lys Pro Gl y Ala Arg Ile  
85 90 95

Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr Trp Pro Gln  
100 105 110

Lys Ser Val Trp His Gl y Ser Asp Pro Asn Gl y Arg Arg Leu Thr Gl u  
115 120 125

Ser Tyr Cys Gl u Thr Trp Arg Thr Gl u Ala Pro Ser Ala Thr Gl y Gl n  
130 135 140

Ala Ser Ser Leu Leu Gl y Gl y Arg Leu Leu Gl y Gl n Ser Ala Ala Ser  
145 150 155 160

0120PCT--000001

Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn Ser Phe Met Thr  
165 170 175

Ala Ser Lys

<210> 26

<211> 180

<212> PRT

<213> EE<sup>1</sup>xD<sup>2</sup>AD

<220>

<223> f »±äl å

<400> 26

Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu  
1 5 10 15

Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe Gln  
20 25 30

Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser  
35 40 45

Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Gly  
50 55 60

Ser Val Pro Ile Val Asn Leu Lys Asp Glu Val Leu Ser Pro Ser Trp  
65 70 75 80

Asp Ser Leu Phe Ser Gly Ser Gln Gly Gln Leu Gln Pro Gly Ala Arg  
85 90 95

Ile Phe Ser Phe Asp Gly Arg Asp Ile Leu Gln Asp Ser Ala Trp Pro  
100 105 110

Gln Lys Ser Val Trp His Gly Ser Asp Ala Lys Gly Arg Arg Leu Pro  
115 120 125

Gl u Ser Tyr Cys Gl u Ala Trp Arg Thr Asp Gl u Arg Gly Thr Ser Gly  
130 135 140

Gln Ala Ser Ser Leu Leu Ser Gly Arg Leu Leu Gl u Gln Lys Ala Ala  
145 150 155 160

Ser Cys His Asn Ser Tyr Ile Val Leu Cys Ile Glu Asn Ser Phe Met  
165 170 175

Thr Ala Ser Lys  
180

<210> 27

<211> 184

0120PCT--000001

<212> PRT  
<213> ÈÈ¹¤ÐòÁÐ

<220>  
<223> Í »±äl å

<400> 27

His Val His Glu Asp Phe Glu Pro Ala Leu His Leu Val Ala Leu Asn  
1 5 10 15

Thr Pro Leu Ser Gly Gly Met Arg Glu Ile Arg Gly Ala Asp Phe Glu  
20 25 30

Cys Phe Glu Glu Ala Arg Glu Val Glu Leu Ala Glu Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Thr Ala Val Pro Ile Val Asn Leu Arg Asp Glu Val Leu Phe  
65 70 75 80

Ser Asn Trp Glu Ala Leu Phe Thr Gly Ser Glu Ala Pro Leu Arg Ala  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Glu Arg Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Glu Lys Ser Val Trp His Glu Ser Asp Pro Asn Glu Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Glu Ala Ser Ser Leu Leu Ala Glu Arg Leu Leu Glu Glu  
145 150 155 160

Lys Ala Ala Glu Cys His Asn Ala Phe Ile Val Leu Cys Ile Glu Asn  
165 170 175

Ser Phe Met Thr Ser Ser Ser Lys  
180

<210> 28  
<211> 185  
<212> PRT  
<213> ÈÈ¹¤ÐòÁÐ

<220>  
<223> Í »±äl å

<400> 28

His Thr His Glu Asp Phe His Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

0120PCT--000001

Thr Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu  
20 25 30

Cys Phe Glu Glu Ala Arg Ala Val Gly Leu Ser Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Glu Ser Gly Ala Gly Lys Thr  
85 90 95

Gly Gly Ala Arg Ile Phe Ser Phe Asp Gly Arg Asp Val Leu Arg His  
100 105 110

Pro Ala Trp Pro Glu Lys Ser Val Trp His Gly Ser Asp Pro Ser Glu  
115 120 125

Arg Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Asp Ser Arg  
130 135 140

Ala Ala Thr Gly Glu Ala Ser Ser Leu Leu Ala Gly Arg Leu Leu Glu  
145 150 155 160

Glu Lys Ala Ala Gly Cys His Asn Ala Phe Ile Val Leu Cys Ile Glu  
165 170 175

Asn Ser Phe Met Thr Ser Ser Lys  
180 185

<210> 29

<211> 183

<212> PRT

<213> ÈÈ¹¤ÐòÁÐ

<220>  
<223> f »±äl å

<400> 29

His Ser His Arg Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu  
20 25 30

Cys Phe Glu Glu Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

0120PCT--000001

Phe Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Arg Asp Val Leu Arg His Pro  
100 105 110

Thr Trp Pro Glu Lys Ser Val Trp His Gly Ser Asp Pro Ser Gly His  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Asp Ser Arg Ala  
130 135 140

Ala Thr Gly Glu Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Glu  
145 150 155 160

Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Ala Asn  
165 170 175

Ser Phe Met Thr Ala Ser Lys  
180

<210> 30

<211> 179

<212> PRT

<213> EEE<sup>1</sup>xDxD

<220>

<223> f »±älå

<400> 30

Asp Phe Glu Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser  
1 5 10 15

Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu Cys Phe Glu Glu  
20 25 30

Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser Ser  
35 40 45

Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala  
50 55 60

Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser Trp Glu  
65 70 75 80

Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Arg Pro Gly Ala Arg Ile  
85 90 95

0120PCT--000001

Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr Leu Pro Gln  
100 105 110

Lys Ser Val Trp His Gly Ser Asp Pro Ser Gly Arg Arg Leu Thr Glu  
115 120 125

Ser Tyr Cys Glu Thr Trp Arg Thr Asp Ser Arg Ala Ala Thr Gly Gln  
130 135 140

Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser Ala Ala Ser  
145 150 155 160

Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn Ser Phe Met Thr  
165 170 175

Ala Ser Lys

<210> 31  
<211> 180  
<212> PRT  
<213> ËÉ¹¤ÐòÁÐ

<220>  
<223> f »±äl å

<400> 31

Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser  
1 5 10 15

Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys Phe Gln Gln  
20 25 30

Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe Leu Ser Ser  
35 40 45

Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala  
50 55 60

Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe Pro Ser Trp Glu  
65 70 75 80

Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Arg Pro Gly Ala Arg Ile  
85 90 95

Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro Thr Leu Pro Gln  
100 105 110

Lys Ser Val Trp His Gly Ser Asp Pro Ser Gly Arg Arg Leu Thr Glu  
115 120 125

0120PCT--000001

Ser Tyr Cys Glu Thr Trp Arg Thr Asp Ser Arg Ala Ala Thr Gly Glu  
130 135 140

Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Glu Ser Ala Ala Ser  
145 150 155 160

Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn Ser Phe Met Thr  
165 170 175

Ala Ser Lys Lys  
180

<210> 32  
<211> 184  
<212> PRT  
<213> EE<sup>1</sup>¤ÐoAD

<220>  
<223> f »±äl å

<400> 32

His Thr His Glu Asp Phe His Pro Val Leu His Leu Val Ala Leu Asn  
1 5 10 15

Thr Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Glu  
20 25 30

Cys Phe Glu Glu Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala  
35 40 45

Phe Leu Ser Ser Arg Leu Glu Asp Leu Tyr Ser Ile Val Arg Arg Ala  
50 55 60

Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe  
65 70 75 80

Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro  
85 90 95

Gly Ala Arg Ile Phe Ser Phe Asp Gly Arg Asp Ile Leu Glu Asp Ser  
100 105 110

Ala Trp Pro Glu Lys Ser Val Trp His Gly Ser Asp Pro Asn Glu Arg  
115 120 125

Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser  
130 135 140

Ala Thr Gly Glu Ala Ser Ser Leu Ser Ser Gly Lys Leu Leu Glu Glu  
145 150 155 160

Ser Val Ser Ser Cys Glu His Ala Phe Val Val Leu Cys Ile Glu Asn  
165 170 175

Ser Phe Met Thr Al a Al a Lys Lys  
180

<210> 33  
<211> 183  
<212> PRT  
<213> EEE<sup>1</sup>xDxD

<220>  
<223> f »±äl å

<400> 33

Thr Pro Thr Trp Tyr Pro Arg Met Leu Arg Val Al a Al a Leu Asn Gl u  
1 5 10 15

Pro Ser Thr Gl y Asp Leu Gl n Gl y Ile Arg Gl y Al a Asp Phe Gl n Cys  
20 25 30

Phe Gl n Gl n Al a Arg Al a Val Gl y Leu Ser Gl y Thr Phe Arg Al a Phe  
35 40 45

Leu Ser Ser Arg Leu Gl n Asp Leu Tyr Ser Ile Val Arg Arg Al a Asp  
50 55 60

Arg Al a Al a Val Pro Ile Val Asn Leu Lys Asp Gl u Val Leu Ser Pro  
65 70 75 80

Ser Trp Asp Ser Leu Phe Ser Gl y Ser Gl n Gl y Gl n Leu Gl n Pro Gl y  
85 90 95

Al a Arg Ile Phe Ser Phe Asp Gl y Lys Asp Val Leu Arg His Pro Thr  
100 105 110

Trp Pro Gl n Lys Ser Val Trp His Gl y Ser Asp Pro Ser Gl y Arg Arg  
115 120 125

Leu Met Gl u Ser Tyr Cys Gl u Thr Trp Arg Thr Gl u Thr Thr Gl y Al a  
130 135 140

Thr Gl y Gl n Al a Ser Ser Leu Leu Gl y Gl y Arg Leu Leu Gl y Gl n Ser  
145 150 155 160

Al a Al a Ser Cys His His Al a Tyr Ile Val Leu Cys Ile Gl u Asn Ser  
165 170 175

Phe Met Thr Asn Asn Arg Lys  
180

<210> 34  
<211> 182  
<212> PRT  
<213> EEE<sup>1</sup>xDxD

0120PCT--000001

<220>  
<223> f »±äl å

<400> 34

His Thr His Thr Ser Gly Pro Gly Leu His Leu Ile Ala Leu Asn Ser  
1 5 10 15

Pro Gln Val Gly Asn Met Arg Gly Ile Arg Gly Ala Asp Phe Gln Cys  
20 25 30

Phe Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala Phe  
35 40 45

Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp  
50 55 60

Arg Ser Ser Val Pro Ile Val Asn Leu Lys Asp Gln Val Leu Ser Pro  
65 70 75 80

Ser Trp Asp Ser Leu Phe Ser Val Ser Gln Gly Gln Leu Gln Pro Gly  
85 90 95

Ala Arg Ile Phe Ser Phe Asp Gly Arg Asp Ile Leu Gln Asp Ser Ala  
100 105 110

Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg Arg  
115 120 125

Leu Thr Gln Ser Tyr Cys Gln Thr Trp Arg Thr Gln Ala Pro Ser Ala  
130 135 140

Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln Ser  
145 150 155 160

Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Gln Asn Ser  
165 170 175

Phe Met Thr Ala Ser Lys  
180

<210> 35  
<211> 31  
<212> DNA  
<213> EE1¤ÐoÁÐ

<220>  
<223> ØýÍí

<400> 35  
ggaattccat atgcacagcc accgcgactt c

31

<210> 36  
<211> 34

0120PCT--000001

<212> DNA  
<213> EE<sup>1</sup>xDxD

<220>  
<223> ØýÍí

<400> 36  
ccgctcgagt tacttggagg cagtcatgaa gctg

34

<210> 37  
<211> 193  
<212> PRT  
<213> EE<sup>1</sup>xDxD

<220>  
<223> f »±äl å

<400> 37

Met Gl y Gl y Ser His His His His His Ser His Arg Asp Phe Gl n  
1 5 10 15

Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser Gl y Gl y Met  
20 25 30

Arg Gl y Ile Arg Gl y Ala Asp Phe Gl n Cys Phe Gl n Gl n Ala Arg Ala  
35 40 45

Val Gl y Leu Ala Gl y Thr Phe Arg Ala Phe Leu Ser Ser Arg Leu Gl n  
50 55 60

Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala Val Pro Ile  
65 70 75 80

Val Asn Leu Lys Asp Gl u Leu Leu Phe Pro Ser Trp Gl u Ala Leu Phe  
85 90 95

Ser Gl y Gl u Ser Gl y Ala Gl y Lys Thr Pro Gl y Ala Arg Ile Phe Ser  
100 105 110

Phe Asp Gl y Lys Asp Val Leu Arg His Pro Thr Trp Pro Gl n Lys Ser  
115 120 125

Val Trp His Gl y Ser Asp Pro Asn Gl y Arg Arg Leu Thr Gl u Ser Tyr  
130 135 140

Cys Gl u Thr Trp Arg Thr Gl u Ala Pro Ser Ala Thr Gl y Gl n Ala Ser  
145 150 155 160

Ser Leu Leu Gl y Gl y Arg Leu Leu Gl y Gl n Ser Ala Ala Ser Cys His  
165 170 175

His Ala Tyr Ile Val Leu Cys Ile Gl u Asn Ser Phe Met Thr Ala Ser  
180 185 190

Lys

<210> 38  
 <211> 192  
 <212> PRT  
 <213> EEE1xDxD

<220>  
 <223> F »±äl å

<400> 38

Met Gl y Gl y Ser His His His His His His Ser His Arg Asp Phe Gl n  
 1 5 10 15

Pro Val Leu His Leu Val Ala Leu Asn Ser Pro Leu Ser Gl y Gl y Met  
 20 25 30

Arg Gl y Ile Arg Gl y Ala Asp Phe Gl n Cys Phe Gl n Gl n Ala Arg Ala  
 35 40 45

Val Gl y Leu Ala Gl y Thr Phe Arg Ala Phe Leu Ser Ser Arg Leu Gl n  
 50 55 60

Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala Val Pro Ile  
 65 70 75 80

Val Asn Leu Lys Asp Gl u Leu Leu Phe Pro Ser Trp Gl u Ala Leu Phe  
 85 90 95

Ser Gl y Ser Gl u Gl y Pro Leu Lys Pro Gl y Ala Arg Ile Phe Ser Phe  
 100 105 110

Asp Gl y Arg Asp Val Leu Arg His Pro Thr Trp Pro Gl n Lys Ser Val  
 115 120 125

Trp His Gl y Ser Asp Pro Ser Gl y His Arg Leu Thr Gl u Ser Tyr Cys  
 130 135 140

Gl u Thr Trp Arg Thr Asp Ser Arg Ala Ala Thr Gl y Gl n Ala Ser Ser  
 145 150 155 160

Leu Leu Gl y Gl y Arg Leu Leu Gl y Gl n Ser Ala Ala Ser Cys His His  
 165 170 175

Ala Tyr Ile Val Leu Cys Ile Ala Asn Ser Phe Met Thr Ala Ser Lys  
 180 185 190

<210> 39  
 <211> 194  
 <212> PRT  
 <213> EEE1xDxD

<220>

0120PCT--000001

<223> I »±äl å

<400> 39

Met Gl y Gl y Ser His His His His His His Thr His Gl n Asp Phe His  
1 5 10 15

Pro Val Leu His Leu Val Ala Leu Asn Thr Pro Leu Ser Gl y Gl y Met  
20 25 30

Arg Gl y Ile Arg Gl y Ala Asp Phe Gl n Cys Phe Gl n Gl n Ala Arg Ala  
35 40 45

Val Gl y Leu Ser Gl y Thr Phe Arg Ala Phe Leu Ser Ser Arg Leu Gl n  
50 55 60

Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala Ala Val Pro Ile  
65 70 75 80

Val Asn Leu Lys Asp Gl u Leu Leu Phe Pro Ser Trp Gl u Ala Leu Phe  
85 90 95

Ser Gl y Gl u Ser Gl y Ala Gl y Lys Thr Gl y Gl y Ala Arg Ile Phe Ser  
100 105 110

Phe Asp Gl y Arg Asp Val Leu Arg His Pro Ala Trp Pro Gl n Lys Ser  
115 120 125

Val Trp His Gl y Ser Asp Pro Ser Gl y Arg Arg Leu Thr Gl u Ser Tyr  
130 135 140

Cys Gl u Thr Trp Arg Thr Asp Ser Arg Ala Ala Thr Gl y Gl n Ala Ser  
145 150 155 160

Ser Leu Leu Ala Gl y Arg Leu Leu Gl u Gl n Lys Ala Ala Gl y Cys His  
165 170 175

Asn Ala Phe Ile Val Leu Cys Ile Gl u Asn Ser Phe Met Thr Ser Ser  
180 185 190

Ser Lys